AI
SPRB

Acuitas Investments’s Spruce Biosciences SPRB Stock Holding History

Acuitas Investments’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,668
Closed -$806K – 136
2023
Q4 		$806K Buy
3,668
+1
+0% +$116 0.42% 80
2023
Q3 		$622K Hold
3,667
– – 0.37% 75
2023
Q2 		$591K Buy
+3,667
New +$613K 0.34% 75

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Acuitas Investments's SPRB Position: Q1 2024 in Review

Acuitas Investments sold out of Spruce Biosciences (SPRB) in Q1 2024, closing a stake of 3,668 shares — an estimated $806K sold.

Acuitas Investments first reported a position in SPRB in Q2 2023 and held it in 3 quarters. The position peaked at $806K in Q4 2023. 49 funds tracked by Wall St. Rank hold SPRB as of Q1 2024.

  • Acuitas Investments reported no remaining Spruce Biosciences position as of Q1 2024 after selling out during the quarter.
  • Acuitas Investments sold 3,668 Spruce Biosciences shares in Q1 2024, an estimated $806K.
  • Acuitas Investments first reported a position in Spruce Biosciences in Q2 2023 and held it in 3 quarters.
  • Acuitas Investments's Spruce Biosciences position peaked at $806K in Q4 2023.
  • 49 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2024.

Based on Acuitas Investments's 13F filing for Q1 2024, filed 10 May 2024.